- Home
- ASM vs VERV Comparison
ASM vs VERV Comparison
Compare ASM & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASM
- VERV
- Stock Information
- Founded
- ASM 1968
- VERV 2018
- Country
- ASM Canada
- VERV United States
- Employees
- ASM N/A
- VERV N/A
- Industry
- ASM Metal Mining
- VERV Medicinal Chemicals and Botanical Products
- Sector
- ASM Basic Materials
- VERV Health Care
- Exchange
- ASM Nasdaq
- VERV Nasdaq
- Market Cap
- ASM 430.0M
- VERV 384.2M
- IPO Year
- ASM N/A
- VERV 2021
- Fundamental
- Price
- ASM $3.17
- VERV $4.45
- Analyst Decision
- ASM Strong Buy
- VERV Strong Buy
- Analyst Count
- ASM 2
- VERV 6
- Target Price
- ASM $2.30
- VERV $25.75
- AVG Volume (30 Days)
- ASM 4.4M
- VERV 2.9M
- Earning Date
- ASM 05-13-2025
- VERV 05-14-2025
- Dividend Yield
- ASM N/A
- VERV N/A
- EPS Growth
- ASM 715.13
- VERV N/A
- EPS
- ASM 0.10
- VERV N/A
- Revenue
- ASM $72,621,000.00
- VERV $59,613,000.00
- Revenue This Year
- ASM $22.93
- VERV $6.18
- Revenue Next Year
- ASM $25.22
- VERV N/A
- P/E Ratio
- ASM $34.81
- VERV N/A
- Revenue Growth
- ASM 56.32
- VERV 271.44
- 52 Week Low
- ASM $0.83
- VERV $2.87
- 52 Week High
- ASM $3.30
- VERV $9.31
- Technical
- Relative Strength Index (RSI)
- ASM 73.63
- VERV 47.78
- Support Level
- ASM $2.98
- VERV $3.89
- Resistance Level
- ASM $3.29
- VERV $4.63
- Average True Range (ATR)
- ASM 0.20
- VERV 0.41
- MACD
- ASM 0.03
- VERV 0.02
- Stochastic Oscillator
- ASM 89.09
- VERV 47.06
About ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.